C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home › Markets › Loading…
HEMP Equity

HEMP

OTCMKTS · HEMP

$0.00
—
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 2/5
46/100 composite
Fundamentals54
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

Hemp Inc carries a Neutral rating, with a composite score in the mid-40s and low conviction. Fundamentals provide the principal support, scoring in the mid-50s on exceptional revenue growth and a gross margin approaching 48%. The regulatory pillar ranks next at just under 50, reflecting a balanced jurisdiction posture and no enforcement hits, offset by weak filing cadence. Market factors remain a drag at 40 because no quote is available through institutional pricing feeds, limiting price discovery and confirmation of investor demand. Editorial momentum is weakest at 30, with no newsroom or brief activity recorded in CIN newsroom coverage. The pillar mix supports the Neutral band rather than a positive rating, as fundamental momentum is not yet reinforced by market visibility, filing recency, or editorial attention.

Licensed fundamentals data show year-over-year revenue growth above 500%, earning the maximum revenue-growth subscore and driving the strongest pillar. Gross margin stands near 48%, producing another substantial contribution. That top-line and gross-profit performance is counterbalanced by an operating margin below negative 2,500%, a zero operating-margin subscore, and a market capitalization of roughly $1.2 million, which also receives no subscore contribution. Reported net income is zero, but the stated financial condition remains stretched; the extreme operating deficit preserves material financing and execution pressure. Primary regulatory filings show no recorded filing date, while the cadence subscore sits at only one-quarter of the available scale. No regulatory events appeared across either the 90-day or 180-day periods, and no enforcement hits were recorded.

The forward case rests on the fundamentals pillar converting extraordinary revenue expansion and a near-48% gross margin into measurable operating improvement. Sustained sales momentum alone cannot lift the rating while operating economics remain deeply negative, market pricing is unavailable, and the filing record lacks recency. A timely primary regulatory filing that confirms continued growth, preserves gross margin, and demonstrates a sharply narrower operating loss would strengthen both the leading pillar and the currently weak regulatory cadence. The single most important signal to watch is operating-margin improvement in the next primary regulatory filing.

Scored: 2026-10-14Valid through: 2026-11-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
Corporate DetailsCompany profile
CEO
Bruce Pe***n
SEC CIK
0001464865
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$1.2M
Enterprise value
$237K
Price to sales
6.44
Revenue (TTM)
$184K
Gross profit (TTM)
$88K
Operating margin
-2554.4%
Profit margin
0.0%
Rev growth YoY
511.5%
Return on equity
-38.7%
Return on assets
-4.6%
EPS (TTM)
$-0.00
Shares outstanding
23,740.5M
Beta
6.56
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for HEMP (HEMP)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for HEMP (HEMP), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Bullish and bearish analyst opinions for Hemp, Inc. (HEMP)

Bullish view. Hemp, Inc. holds industrial-hemp processing assets and land positions in North Carolina; a turnaround thesis would centre on monetising infrastructure into contract processing revenue as US hemp reform matures.

Bearish view. Bears highlight the very-small-cap OTC listing profile, going-concern signals in prior filings, dilutive financing history, and thin secondary-market liquidity.

Live ratings, price targets, and consensus figures for Hemp, Inc. appear above this summary. Explore analyst coverage across the 326-equity cannabis universe.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for HEMP are maintained by Cannabis Investor News and refreshed throughout the trading day.